Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
News-Medical.Net

Targeting super-enhancer mechanisms offers new strategies for cancer therapy

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain ...

Rivals High School Girls Flag Football Top 25 Rankings – Apr. 13

The national high school girls flag football scene has surged in popularity nationwide, featuring many strong programs across ...